An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1098
Full Text
Open PDFAbstract
Available in full text
Date
December 19, 2016
Authors
Publisher
American Association for Cancer Research (AACR)